Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation
Phase 1 Completed
85 enrolled
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma
Phase 1 Completed
20 enrolled
Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients
Phase 3 Completed
482 enrolled 1 FDA
A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders
Phase 1/2 Completed
58 enrolled
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
Phase 2 Completed
87 enrolled 19 charts
MK-4280-003
Phase 1/2 Completed
137 enrolled
A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma
Phase 1 Completed
3 enrolled
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Phase 1/2 Completed
803 enrolled 2 FDA
Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)
Phase NA Completed
10 enrolled
STAY-STRONG
Phase NA Completed
42 enrolled
Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy
Phase 2 Completed
27 enrolled 15 charts
Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
Phase 1/2 Completed
45 enrolled
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
Phase 1 Completed
26 enrolled
LNH2007-3B
Phase 2 Completed
222 enrolled
CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia
Phase 1 Completed
18 enrolled
INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
Phase 1 Completed
50 enrolled
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
Phase 1 Completed
52 enrolled
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Phase 1 Completed
54 enrolled 24 charts
Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)
Phase 1 Completed
12 enrolled
A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects
Phase 1 Completed
25 enrolled
A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma
Phase 1 Completed
10 enrolled
Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)
Phase 1 Completed
10 enrolled
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
Phase 1 Completed
8 enrolled
Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma
Phase 1 Completed
29 enrolled 13 charts
HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Phase 1 Completed
89 enrolled
KEYNOTE-A33
Phase 1 Completed
7 enrolled 13 charts
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Phase 1/2 Completed
64 enrolled 13 charts
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
Phase 2 Completed
104 enrolled 29 charts
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Phase 3 Completed
838 enrolled 16 charts
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
Phase 1 Completed
11 enrolled 16 charts
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
Phase 1 Completed
111 enrolled
CAPITAL
Phase 2 Completed
30 enrolled 15 charts
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
Phase 1/2 Completed
117 enrolled 26 charts
CAR-37 T Cells in Hematologic Malignancies
Phase 1 Completed
6 enrolled
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas
Phase 1 Completed
14 enrolled
A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies
Phase 1 Completed
72 enrolled
SCNSL1
Phase 2 Completed
40 enrolled 11 charts
ZUMA-12
Phase 2 Completed
42 enrolled 20 charts
MB-CART20.1 Lymphoma
Phase 1/2 Completed
10 enrolled
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
Phase 1 Completed
154 enrolled
MargheRITA
Phase NA Completed
124 enrolled
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
Phase 1 Completed
18 enrolled
CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies
Phase 2 Completed
77 enrolled
Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma
Phase 1 Completed
65 enrolled
BIANCA
Phase 2 Completed
34 enrolled 19 charts
Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL
Phase 2 Completed
100 enrolled 21 charts
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Phase 1 Completed
70 enrolled
A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy
Phase 1 Completed
13 enrolled
Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy
Phase NA Completed
45 enrolled
A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Phase 1 Completed
24 enrolled